Analyst Price Target is $4.50
▼ -13.46% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Molecular Partners in the last 3 months. The average price target is $4.50, with a high forecast of $4.50 and a low forecast of $4.50. The average price target represents a -13.46% upside from the last price of $5.20.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Molecular Partners. This rating has held steady since September 2024, when it changed from a Hold consensus rating.
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Read More
